S_ay The presence of specific and high affinity epidermal growth factor receptors (EGF-R) has 
The high incidence of prostatic cancer (CaP) has led to intensified study of this gland during the past two decades. The nature of the molecular changes responsible for the disease has attracted the attention of many biochemists and molecular biologists, but the complete solution to the cancer problem still eludes the best efforts of both scientists and clinicians. Early diagnosis and treatment are crucial. In this connection a considerable amount of work on a variety of substances synthesised and secreted by the prostate has been carried out in order to gain insight into the pathogenesis of this condition (Choe & Rose, 1982; Pontes et al., 1982) . Recently interest has focused on the many peptide growth factors because of their regulatory action on tissue growth (Sporn & Roberts, 1988) .
Of particular interest is the epidermal growth factor (EGF) polypeptide (molecular weight 6,045 daltons) which stimulates proliferation and differentiation of a great vanrety of cell types (Carpenter & Cohen, 1979) . The activities of EGF are mediated through its specific receptor, which is a 170 kilodalton glycoprotein located on the cell surface membrane. Several reports showed that the binding activity of EGF to the receptor in cancerous tissues was either decreased (De Larco & Todaro, 1978) or increased (Libermann et al., 1985; Cowley et al., 1986) . Furthermore, the receptor expression has been correlated with the metastatic potential of the cancer (Gusterson et al., 1984; Sainsbury et al., 1985; Neal et al., 1985; Cowley et al., 1986; Gullick et al., 1986) . Recent evidence indicates that the oncogene v-erbB encodes a truncated EGF receptor which activates the tyrosine kinase to a 'turned on' state, thereby obviating the need for EGF stimulation (Downward et al., 1984) . The receptor was therefore thought to have some role in the biological behaviour of carcinoma cells. Although the localisation of EGF receptors (EGF-R) in human benign prostatic hyperplasia (BPH) has been established (Maddy et al., 1987) and the importance of EGF in maintaining prostate cell proliferation has been demonstrated (Chaproniere & McKeehan, 1986) (Gleason, 1977) . This system is based upon the degree of glandular differentiation and the growth pattern of the tumour in relation to the prostatic stroma. The Gleason grade consists of two numbers, each between 1 and 5, which designate the primary and secondary pattern according to the amount of each present in the specimen. The sum of the two numbers is called the Gleason score and it may range from 2 to 10. The remainder of the tissue was either used fresh or snap frozen in liquid nitrogen and stored at -70-C until analysis. None of the cancer patients had received any therapy -endocrine or otherwise -before entry into this study.
Tissue preparation
The following procedures were carried out at 4-C according to the method described by Maddy et al. (1987 labelled EGF and I00pl sample. Incubation took place at 37-C for 90 mmn and the reaction was terminated by the addition of 1 ml of buffer B. Thereafter the bound complex was separated from the free by PEG precipitation (Hwang et al., 1986) . The specific binding was calculated by subtracting the non-specific from the total binding. Validation of the assay for time and temperature of incubation, protein concentration and optimal pH range has already been established and described in detail (Maddy et al., 1987 Figure 2 .
The specificity of the binding was also examined employing vNGF, hLH, hFSH, human-insulin, hGH, humanprolactin and mnEGF at 500, 750, 1,000, 1,500 and 3,000ngml-1 as competitors. The data shown in Figure 3 reveal that the unlabelled mEGF competed in a dose related manner with 124I-labelled mEGF for the binding sites whereas the other ligands investigated did not displace the labelled ligand from its binding sites.
Because of the significant difference between the mean EGF-R values for the BPH and CaP groups, we decided to analyse the receptor results of the cancerous specimens in more detail. Tumours were classified according to their histological grade (Gleason score: primary + secondary pattern) and these were in turn correlated to their various receptor levels. The results illustrated in Figure 4 suggest a significant correlation between the Gleason score and receptor concentrations: high receptor levels (mean = 84 + 13 fmol mg protein -1) were always associated with good tumour differentiation (Gleason score 2-4) whereas poorly differentiated cancers (Gleason score demonstrated receptor concentrations (53+8ffmolmgprotein-1) which were significantly lower than those measured in the well differentiated tumours but higher than the receptors associated with poorly differentiated CaP. The differences between the three groups were statistically significant (P<O.01). Although other reports have established the presence of EGF-R in human BPH (Maddy et al., 1987; Eaton et al., 1988) , this is the first time that a significant correlation has been demonstrated between the expression of EGF-R and tumour differentiation in cancer of the human prostate. In the present study 19 prostatic cancers of varying degrees of differentiation were examined for their EGF-R concentrations and these measurements were in turn compared with those obtained in benign prostatic hyperplasia from an aged matched group. Our data indicated significant differences in EGF-R concentrations for both tissue types with the mean value of the cancer tissue being markedly depleted when compared to the hyperplastic specimens (P<0.01). Furthermore, grouping of the tumours according to their histological grade indicated that there was a diminished propensity to express EGF-R as tumours progressively became less differentiated; in this respect EGF-R could be used as further confirmatory evidence for the histopathological grading of CaP. In the present study we chose the Gleason grading system (Gleason, 1977) as an index of the degree of differentiation because it provides a more detailed insight into the nature of any particular tumour than the simple three grade system (Beynon et al., 1983) .
These findings are supported by other workers who also demonstrated that the receptor expressions with a variety of other tissues in the cancer state were inversely proportional to the metastatic potential of the tumour. Thus increased levels of EGF-R expression were associated with well differentiated tumours whereas poorly differentiated cancers correlated with a reduced receptor expression (Gusterson et al., 1984; Gullick et al., 1986) . However, these trends are not universal, as shown by the recent studies on breast cancer (Sainsbury et al., 1985) . invasive and superficial bladder cancer (Neal et al., 1985) and squamous carcinoma cells (Ozanne et al., 1985; Cowley et al., 1986) where EGF-R expression was significantly amplified as the tumours progressed to the metastatic state. Of interest too are the dissociation constant values for CaP which are of the same order of magnitude as those previously measured in BPH (Maddy et al., 1987 ). Our results demonstrate that the reduced binding capacity of CaP is not induced by changes in the affinity of the receptor for its ligand; such changes are not uncommon and have been reported in earlier studies on human oesophagus carcinoma cells (Banks-Schlegel & Quintero, 1986) .
The mechanisms by which EGF-Rs are implicated in the malignant transformation are not well defined but one possibility for the increase in receptor levels stems from an amplification and rearrangement of the receptor gene (Bradley et al., 1986) . Loss of receptors, on the other hand, has been attributed to several factors, of which internalisation (Kay et al., 1986) , expression of truncated EGF receptors (Ozanne et al., 1984) and total absence of EGF-R gene expression (Robinson et al., 1982) are the most likely to be involved. We are at present considering all these possibilities with a view to identifying the causes responsible for EGF-R depletion in cancer of the prostate.
